Cytochrome b5 and Cytokeratin 17 Are Biomarkers in Bronchoalveolar Fluid Signifying Onset of Acute Lung Injury by Ménoret, Antoine et al.
University of Connecticut
OpenCommons@UConn
UCHC Articles - Research University of Connecticut Health Center Research
7-6-2012
Cytochrome b5 and Cytokeratin 17 Are
Biomarkers in Bronchoalveolar Fluid Signifying
Onset of Acute Lung Injury
Antoine Ménoret
University of Connecticut School of Medicine and Dentistry
Sanjeev Kumar
University of Connecticut School of Medicine and Dentistry
Anthony T. Vella
University of Connecticut School of Medicine and Dentistry
Follow this and additional works at: https://opencommons.uconn.edu/uchcres_articles
Part of the Medicine and Health Sciences Commons
Recommended Citation
Ménoret, Antoine; Kumar, Sanjeev; and Vella, Anthony T., "Cytochrome b5 and Cytokeratin 17 Are Biomarkers in Bronchoalveolar
Fluid Signifying Onset of Acute Lung Injury" (2012). UCHC Articles - Research. 94.
https://opencommons.uconn.edu/uchcres_articles/94
Cytochrome b5 and Cytokeratin 17 Are Biomarkers in
Bronchoalveolar Fluid Signifying Onset of Acute Lung
Injury
Antoine Me´noret, Sanjeev Kumar, Anthony T. Vella*
University of Connecticut Health Center, Farmington, Connecticut, United States of America
Abstract
Acute lung injury (ALI) is characterized by pulmonary edema and acute inflammation leading to pulmonary dysfunction and
potentially death. Early medical intervention may ameliorate the severity of ALI, but unfortunately, there are no reliable
biomarkers for early diagnosis. We screened for biomarkers in a mouse model of ALI. In this model, inhalation of S. aureus
enterotoxin A causes increased capillary permeability, cell damage, and increase protein and cytokine concentration in the
lungs. We set out to find predictive biomarkers of ALI in bronchoalveolar lavage (BAL) fluid before the onset of clinical
manifestations. A cutting edge proteomic approach was used to compare BAL fluid harvested 16 h post S. aureus
enterotoxin A inhalation versus BAL fluid from vehicle alone treated mice. The proteomic PF 2D platform permitted
comparative analysis of proteomic maps and mass spectrometry identified cytochrome b5 and cytokeratin 17 in BAL fluid of
mice challenged with S. aureus enterotoxin A. Validation of cytochrome b5 showed tropic expression in epithelial cells of the
bronchioles. Importantly, S. aureus enterotoxin A inhalation significantly decreased cytochrome b5 during the onset of lung
injury. Validation of cytokeratin 17 showed ubiquitous expression in lung tissue and increased presence in BAL fluid after S.
aureus enterotoxin A inhalation. Therefore, these new biomarkers may be predictive of ALI onset in patients and could
provide insight regarding the basis of lung injury and inflammation.
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Introduction
Pulmonary biomarkers are needed to predict the clinical course
of lung disease, status, progression, and response to treatment
[1,2]. A key aspect in biomarker discovery is uncovering molecules
that appear early during disease initiation, when the natural
history of the disease can be modified. During acute lung injury
(ALI), several factors correlate with tissue damage such as
recruitment of neutrophils and macrophages, and also increases
in IFNc in BAL fluid [3]. However, these events occur late in the
disease process, once ALI is fully initiated. Therefore, it is critical
to find new biomarkers that occur prior to tissue damage [4] and
perhaps even before cytokines are produced.
In humans, a major cause of ALI is the immune response to a
lung infection [5,6]. Naturally there are other causes such as
exposure to aerosolized toxic chemicals, aspiration, and multiple
trauma. However, even in these cases, a secondary infection may
trigger the inflammatory response that leads to ALI [6]. Although
no animal model is a perfect representation of ALI in humans [7],
bacterial lipopolysaccharide (LPS) does induce key features such as
alveolitis, neutrophil recruitment, and induction of IFNc that
mimic symptoms of human ALI. However, unlike infection with
whole organisms, LPS does not specifically stimulate T cells, which
likely make a substantial contribution to disease in humans.
Therefore, pathogen byproducts that stimulate T cells add a
critical dimension to the modeling of human ALI.
Staphylococcus aureus secretes enterotoxin proteins that are
pathogenic in humans, can cause toxic shock syndrome [4],
and are implicated in Chronic Obstructive Pulmonary Disease
(COPD) [8]. Importantly, S. aureus has been detected in nasal
polyps of patients suffering from chronic rhinosinusitis, and IgE
antibodies specific to S. aureus enterotoxin A (SEA) have been
detected in patients with severe asthma, suggesting that SEA is
involved in the pulmonary immune response [9,10]. In our
previous mouse study we showed that inhalation of SEA
induced T cells to migrate into lung, become effectors, and
prime innate cells [11]. This response was rapid, marked by
neutrophil recruitment and increases of protein in BAL fluid
along with high levels of IFNc and alveolitis. Consequently, the
SEA inhalation model approximates many aspects of human
ALI.
Our goal was to use a proteomic mining strategy to uncover
differences in BAL fluid from SEA treated mice versus vehicle
alone controls. The PF 2D proteomic platform allows two-
dimensional liquid fractionation of biological fluid based on
isoelectric focusing and hydrophobicity. We used this strategy to
detect changes during colon cancer chemoprevention [12], and
others have used it for biomarker discovery [13,14]. Recently,
this method uncovered a pathway involved in cytokine based
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inflammation [15]. Therefore, we set out to find distinct
changes in the BAL fluid proteome of SEA treated mice
compared to vehicle alone, and found an unexpected increase
in microsomal cytochrome b5 and cytokeratin 17. These data
were validated and coincided with rapid changes in lung
pathology that included increased lung inflammation. Thus, our
mouse model data show that cytochrome b5 and cytokeratin 17
are detected in BAL fluid very early after lung damage, and
thus may be potential biomarkers of pulmonary injury in
patients with ALI or other life-threatening diseases.
Results
Inhalation of SEA Induces Lung Inflammation and
Damage
We used an in vivo mouse model of ALI to uncover molecular
biomarkers of lung inflammation. After inhalation of SEA, mice
were monitored for signs of acute inflammation. In the current
study we first examined lung pathology 2 days post SEA
challenge, a time point where T cell effectors start to
accumulate [11]. Lung sections stained by hematoxylin and
eosin (H&E) showed leakage of red blood cells from blood
vessels into the alveoli (Fig. 1A, black arrows in upper right
panel), abundant leukocyte infiltration in the peri-vascular tissue,
and increased cellularity in the interstitium and alveolar space
as we observed previously [11]. Proteinous exudate was visible
after SEA (Fig. 1A, white arrows in upper right panel). In
contrast, lungs from vehicle-treated mice showed no signs of
injury (Fig. 1A lower panels). To visualize the possibility of
increased infiltrating leukocytes we performed the same inhala-
tion study with or without lung perfusion. We found that
perfusing the lung allowed for visualization of adherent
leukocytes in the lumen of blood vessels after SEA treatment
in the lung sections (Fig. 1B). In the absence of inflammation
(vehicle) leukocyte adhesion was not evident. Secondly, electron
microscopy (EM) was used to demonstrate the binding of
leukocytes to the vascular lung endothelium. EM showed
increased leukocyte adherence to blood vessel endothelium in
the lung airways after SEA inhalation whereas vehicle alone
injected mice showed no sign of leukocyte infiltration or
adhesion to the endothelium (Fig. 1C). Moreover, leukocytes
appeared to be transmigrating from the vasculature into lung
tissue (Fig. 1C, left panel: L*). Altogether, these pathologic
changes are consistent with rapid inflammation and immune-
mediated lung damage.
Next, we measured parameters representative of ALI and tested
the effect of 2u inhalation of SEA at inducing compounded
inflammation. Increased cell number and total protein in BAL was
evident (Figs. 2A and 2B). High levels of IFNc and IL-6 were
detected in BAL fluid after SEA inhalation and were strongly
augmented after 2u SEA (Figs. 2C and E). Additionally, IFNc and
IL-6 were detected in serum demonstrating a powerful systemic
response, which is a key factor in modeling ALI (Figs. 2D and F).
Finally, lactate dehydrogenases (LDH), a marker of cell injury
detectable in BAL fluid [16,17] was present in BAL fluid but there
was no difference after SEA inhalation (Fig. 2G). In fact, this result
reinforces the current consensus for the need of new and more
sensitive biochemical markers for ALI [1,2].
Identification of Early Markers of ALI
To identify biomarkers of lung injury we used a proteomic
approach comparing BAL fluid of SEA versus vehicle alone
treated mice. Importantly, in order to find early biomarkers of
ALI we collected BAL fluid 16 h after SEA inhalation and
analyzed the samples using a PF 2D proteomics platform as
described before [12,15]. PF 2D proteomics enables protein
separation by charge followed by reverse-phase chromatography
(Fig. 3). Proteomic maps of BAL fluid SEA versus vehicle alone
were similar as illustrated (Fig. 3A), but 2 peaks were spotted as
Figure 1. Intranasal SEA challenge induces lung injury and
leukocyte infiltrate. Mice received 1 mg of SEA diluted in BSS
(Vehicle) through the i.n. route. (A) Lungs from day 2 SEA challenged
mice were isolated, sectioned, and stained with H&E. Left panels display
a low magnification (100X) and right panels high magnification (400X)
of representative lung sections. Black arrows indicate leakage of red
blood cells, white arrows indicate eosin staining refractile material
(protein). (B) High magnification (400X) of lungs with (left panel) and
without perfusion (right panel) of representative lung sections after
vehicle alone and SEA i.n inhalation. Arrows indicate infiltrating
leukocytes retained in blood vessel after perfusion. (C) Electron
microscopy of lung blood vessels after vehicle alone and SEA i.n
inhalation: Alveoli (Alv), Blood Vessel (B.Ves.), Erythrocyte (e), Leukocyte
(L), Transmigrating leukocyte (L*). Bar = 10 mm. The data are
representative of three independent experiments using 2–4 mice per
group.
doi:10.1371/journal.pone.0040184.g001
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differential fingerprints (Fig. 3A dotted circle). After careful
analysis of three independent experiments using Proteoview
software, two fingerprints were consistently identified at specific
coordinates present in the BAL fluid map from 16 h SEA
treated mice but absent or reduced in vehicle alone samples
(Fig. 3B, right boxes). To identify the proteins contained in the
differential fingerprint fractions, a third dimension was used.
The fractions of interest were lyophilized, resolved by SDS-
PAGE, and detected by fluorescent dye staining (Fig. 3C). The
bands uniquely detected in the SEA BAL fluid samples were cut
out of the gel, digested with trypsin and proteins identified by
LC/MS/MS (Fig. 3D). Using this strategy cytochrome b5 and
cytokeratin 17 were identified as differentially present upon SEA
inhalation. Importantly, the sequences of cytochrome b5 and of
cytokeratin 17 indicated the proteins were derived from mouse
and were not contaminants of human origin. Interestingly, the
molecular weight of cytochrome b5 corresponds to the
migrating size (15 kDa) of the band on SDS-PAGE suggesting
that the full length protein was isolated (Fig. 3D). All the other
identified proteins had a higher molecular weight suggesting a
breakdown product of these proteins were isolated. Several
proteins like albumin and haptoglobin, known to be associated
with inflammation and injury [18,19] serve as a validation
component of our analysis.
Cytochrome b5 is a Marker of Lung Damage
We performed immunohistochemistry analysis of the proteins
with the greatest spectral count as assessed by mass spectrometry
(Fig. 3D) to validate their expression and to pinpoint from which
site in the lung these proteins were derived. Staining for
cytochrome b5 showed strong expression restricted to the
epithelium of lung airways (Fig. 4A, top panels). Interestingly,
the staining was quite evident in the airways of the vehicle alone
treated group (Fig. 4A upper left panel), but weaker and
punctuated in the 3 groups that received SEA (Fig. 4A the three
upper right panels). This observation is consistent with the notion
that cytochrome b5 may be released from epithelial cells of lung
airways that are damaged locally by activated immune cells
following SEA inhalation. To provide support for this notion,
cytochrome b5 staining intensity was determined using Image-Pro
Plus software and the data showed a significant decrease of
staining in all groups that received SEA versus vehicle alone
(Fig. 4B).
We also validated the expression of cytokeratin 17 that is
ubiquitously expressed in lung tissue, but contrary to cytochrome
b5, the tissue expression of cytokeratin 17 in the lung was not
visibly altered by SEA inhalation (Fig. 5a). We further validated
the presence of cytokeratin 17 using immunoblot (Fig. 5b).
Cytokeratin 17 accumulated in BAL fluid as early as 4 h post-
SEA (Fig 5c) and a longer exposure of the membrane revealed
cytokeratin 17 in BAL fluid from naı¨ve mice (Fig 5c) and in vehicle
alone BAL fluid (Fig. S1). Thus, cytokeratin 17 is sensitive to
perturbations in lung. Immunoblotting for cytochrome b5 was less
successful since a 60 kDa, instead of a 15 kDa, band was routinely
detected which might have been a concatemer of cytochrome b5
as previously published (not shown) [20]. Altogether our data raise
the possibility that cytochrome b5 and cytokeratin 17 are potential
biomarkers of lung injury released from damaged epithelium early
during pulmonary inflammation.
Discussion
Using a proteomic-based approach we compared proteomic
maps between BAL fluid from SEA versus vehicle-challenged mice
and uncovered the presence of cytochrome b5 right after the onset
of inflammation. Cytochrome b5 expression was restricted to
epithelial cells of the bronchioles and SEA inhalation decreased
the intensity of its signal. We propose that inflammation caused by
cell injury mediates rapid release of cytochrome b5 into the
extracellular space. Alternatively, cellular cytochrome b5 may be
shed in the early stages of lung injury and found in the BAL fluid.
Hence, cytochrome b5 is a potential biomarker of early lung
injury.
Previous studies, and the model presented in this report,
demonstrate that enterotoxin inhalation induces rapid T cell and
innate cell activation that mimic the characteristics of human lung
injury. These include acute onset of disease, obstruction of the
airways [11,21,22], increased vascular permeability (Fig. 1) [22],
endothelial and epithelial damage [21] (Fig. 1), production of nitric
oxide [23], and increase protein and cytokine concentration in the
lungs [11,21,22,23] (Fig. 2). Hence, SEA inhalation in mouse
provides a useful animal model of ALI that complements other
experimental approaches [7]. In this report we specifically show
rapid onset of protein deposition, leakage of red blood cells,
increased adhesion of leukocytes in small blood vessels, leukocyte
infiltration, and accumulation of proteins and cytokines in BAL
fluid (Figs. 1–2). These data firmly establish that SEA inhalation
can induce ALI.
The search for biomarkers of lung injury has provided
candidates expressed in different anatomical compartments [24].
The von Willebrand factor (vWF) and ICAM-1 have been
proposed as predictive markers of endothelial injury but with
mixed results [25,26,27]. Surfactant proteins SP-A and SP-D
expressed by type II pneumocytes, the receptor for advance
glycation end-product (RAGE), and KL-6 have been associated
with pulmonary epithelial cell damage [28,29,30,31]. Desomosine,
a stable fragment of elastine, has been used as a marker for
destroyed extracellular matrix in ALI [32,33]. Moreover, the
presence of inflammatory cytokines present during ALI is often
associated with a negative prognosis. For example, IL-1b, IL-6, IL-
8, and IL-10 are associated with morbidity and mortality in ALI
patients [34,35]. However, the etiology of the disease and the
presence of infectious agents promoting inflammation add to the
complexity of finding the appropriate biomarker [25]. Although
biomarkers of ALI have been identified, no single biomarker has
been successfully used to diagnose and predict the clinical course
of the disease [1,2]. However, the combination of a panel of
multiple biomarkers has been shown to be an improvement for
predicting mortality in acute lung injury [36] and reinforces the
idea that finding additional new early biomarkers will increase the
accuracy of diagnosis.
To better understand the onset of lung injury the PF 2D was
used to detect proteins in BAL fluid. Comparative proteomic
mapping of BAL fluid taken from mice after SEA inhalation
uncovered cytochrome b5 as a putative biomarker. Among the
Figure 2. Intranasal SEA challenge induces cellular infiltration, protein leakage and inflammation. Mice received 1 mg of SEA or vehicle
alone i.n., secondary (2u) challenge of either vehicle or SEA 48 h after the primary (1u) and were sacrificed 5 h later (53 hrs total). (A) Cells present in
BAL fluid were harvested and enumerated and (B) total BAL fluid protein quantified by BCA. (C) IFNc in BAL fluid and (D) in serum, and (E) IL-6 in BAL
and (F) in serum were quantified by ELISA. (G) LDH in BAL fluid was quantified. The data are representative of two independent experiments using 4
mice per group. The errors bars indicate the standard error of the mean between biological replicates.
doi:10.1371/journal.pone.0040184.g002
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different isoforms of cytochrome b5, we identified the isoform
bound to the ER membrane, called microsomal cytochrome b5
[37]. Following PF 2D fractionation, LC/MS/MS resolved 8
unique peptides covering 43% of microsomal cytochrome b5
sequence with perfect homology. However, a truncated soluble
form of cytochrome b5 encoded by a second gene lacking the
membrane binding carboxy terminus and expressed in erythro-
cytes, lung, gallbladder, adrenal gland, and bone marrow [38]
matches the peptide sequences. Nevertheless, the molecular size
of the protein isolated by PF 2D fractionation corresponded to
the membrane bound microsomal and not soluble cytochrome
b5. Additional genetic studies will be needed to confirm with
absolute certainty which form of cytochrome b5 has been
identified in our study. However, we ruled out OMb, the
mitochrondrial isoform of cytochrome b5 [39], which has only
58% amino acid conservation with microsomal cytochrome b5
[40]. Cytochrome b5 is a highly conserved protein involved in
electron transfer between NADH/NADPH and cytochrome
P450, participating in the oxidation of a wide array of
endogenous and xenobiotic substances [37,41]. The use of
model substrates and drugs in conditional hepatic knock-out
cytochrome b5 mice demonstrated that P450-mediated metab-
olism is dependent on cytochrome b5 [42]. Interestingly,
systemic LPS administration decreases cytochrome P450 mRNA
expression in lungs [43], which support the finding that
inhibitors of cytochrome P450 activity exacerbate LPS-mediated
inflammation while compounds known to induce cytochrome
P450 reduce inflammation [44]. Thus, cytochrome b5 may
influence inflammatory responses by impacting P450 function.
Additionally, some of the immunomodulatory proteins released
from lung epithelial cells, such as CC16 [45], surfactant proteins
[46,47], and galectin-3 [48] are considered damage-associated
molecular-patterns (DAMPs) [49]. Therefore, cellular damage
could induce release of DAMPs and aggravate ALI. We
identified cytochrome b5 and cytokeratin 17 by focusing on
the most prominent and reproducible differences apparent on
our proteomic maps. However, it is possible that known
DAMPs were present in the BAL fluid but not identified.
Some of the biomarkers identified in our study could potentially
be DAMPs and worsen lung injury by promoting the inflamma-
tory response. For example, cytokeratin 17, which we detected in
the BAL fluid after SEA inhalation, can trigger cytokine
production and inflammation in vivo [50]. Thus, the presence of
proteins in BAL fluid after SEA inhalation may enhance lung
inflammation. To the best of our knowledge the immunomodu-
latory effect of cytochrome b5 is unknown, but our results show
that cytochrome b5 is modulated during the early stages of lung
cell injury and perhaps represent a new target for therapeutic
intervention.
Materials and Methods
Mice
C57BL/6 mice were purchased from the National Cancer
Institute (Frederick, MD) or the Jackson Laboratory (Bar Harbor,
ME). All mice were maintained in the central animal facility at
the University of Connecticut Health Center (UCHC) in
accordance with federal guidelines. The present study was
Figure 3. Differential proteomic fingerprint of BAL fluid from
SEA vs. vehicle alone injected mice. Mice were immunized as
described in the legend of figure 1. After 16 h BAL fluid was obtained
and 2 mg of protein per sample was processed on the Beckman Coulter
ProteomeLab PF 2D platform. Chromatofocusing was performed as a
linear gradient from pH 8.0 to pH 4.0. Fractions were collected in
0.3 pH intervals, automatically reinjected for a second dimension on a
C18 column at 50uC. (A) Two-dimensional proteomic maps of BAL fluid
from SEA and vehicle alone immunized mice, representative of one out
three experiments is shown. (B) Chromatograms of second dimension
fractions from SEA treated mice were overlaid with their corresponding
equivalents from vehicle alone-injected mice. Overlays revealed peaks
present in two fractions of the SEA treated samples but undetectable in
the vehicle alone injected samples. (C) The fractions were lyophilized
and resolved by 4–15% SDS-PAGE. Bands detected by a protein-specific
fluorescent dye were cut out, digested by trypsin, and identified by LC/
MS/MS. (D) Peptides sequences were searched against the NCBInr
database version 20060804 using the Proteometrics Software Suite and
the Profound Search Algorithm. The data are representative of three
independent biological replicates. Each sample run on the PF 2D was a
pool of BAL fluid obtained from 5 mice.
doi:10.1371/journal.pone.0040184.g003
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approved by the University of Connecticut Health Center’s
Animal Care Committee.
Antibodies and ELISA
IFNc and IL-6 ELISA kits were purchased from Pharmingen
(Mountain View, CA). Anti-cytochrome b5 rabbit polyclonal
antibody was purchased from Abcam (Cambridge, MA). Anti-
cytokeratin 17 rabbit polyclonal antibody was purchased from
Santa Cruz Biotechnology (Santa Cruz, CA). LDH detection kit
was purchased from Cell Sciences (Canton, MA).
Microscopy
PBS/heparin solution was used for perfusion. Lungs were
inflated with 10% formalin solution, clamped for 5 min, fixed
for 2 h and stored in 70% ethanol before paraffin embedding.
Lung sections were stained for H&E or stained with the
appropriate antibody for immunohistochemistry (IHC) and
counter stained with methyl green (Vector laboratory, Inc.
Burlingame, CA). The percentage of bronchiole cells staining
positive for cytochrome b5 was quantified using Image-Pro Plus
software (Media Cybernetics, Inc. Bethesda, MD). Pixel analysis
was performed on 30 representative bronchioles for each
condition. Data was reported as the percentage of positive
staining area (brown) versus total staining area (all colors) present
in each bronchiole. Lung sections for Electron Microscopy were
processed at the central microscope facility, University of
Connecticut Health Center. Lungs were fixed in 2.5%
glutaraldehyde in 0.1M cacodylate buffer pH 7.2, post fixed
in 1% osmium tetroxide, 0.8% potassium ferricyanide in 0.1M
cacodyalte buffer, en-bloc stained with uranyl acetate, dehy-
drated in ethanol and embedded in Polybed 812 resin. Thin
sections (70 nm) of the lungs were cut and counterstained with
uranyl acetate and lead citrate. Thin sections were examined
using a Hitachi H-7650 transmission electron microscope.
BAL Fluid Processing and PF 2D Proteomics
BAL was collected by lavage of mouse lung with 5 ml of
sterile PBS. BAL was centrifuged at 1,000 rpm at 4uC to
separate cells from BAL fluid. BAL fluid was spiked with a
protease inhibitor cocktail (SIGMA #P2714), centrifuged at
25,000 x g, 4uC for 10 min, protein concentration was
determined by BCA assay (Pierce, Rockford, IL), and processed
through a Beckman Coulter ProteomeLabTM PF 2D platform
(Fullerton, CA) as described before [12,15,51]. Fractions were
collected every 0.3 pH units. Fractions corresponding to the
linear gradient between pH 8.0 through 4.0 were separated on
a HPRP column (Beckman Coulter) with a gradient from 0 to
100% of acetonitrile at 50uC. The proteins were detected with
Figure 4. Cytochrome b5 expression is restricted to bronchiole epithelium in lungs. Mice were immunized i.n. with 1 mg of SEA or vehicle
alone i.n., secondary (2u) challenge of either vehicle or SEA 48 h after the primary, and were sacrificed 5 h later (53 hrs total). (A) Immunostaining of
the lungs was performed using a rabbit polyclonal antibody against cytochrome b5 (Cyt b5) and rabbit immunoglobulin control (Ig). The data are
representative of three independent experiments with 2–4 mice per group, magnification 100X. (B) The percentage of positive cytochrome b5
staining per bronchiole is reported for each sample by analyzing 30 representative bronchioles from two separate experiments. The errors bars
indicate the standard error of the mean. **p,0.001.
doi:10.1371/journal.pone.0040184.g004
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UV light at 214 nm and collected at 0.5 min intervals and
stored at 280uC.
Two Dimensional (2D) Protein Map Analysis
Two dimensional protein expression maps of BAL fluid
displaying protein isoelectric point (pI) versus protein hydropho-
bicity, were generated by the ProteoView/DeltaVue software
package as described earlier [12,15].
SDS-PAGE, Immunoblotting, Fluorescence Staining, and
LC/MS/MS
The PF 2D fractions of interest were lyophilized and
resuspended in denaturing SDS sample buffer and resolved by
SDS-PAGE and immunoblotting as described earlier [15]. Gels
were stained by ORIOLE (BioRad, Hercules, CA) and proteins
were detected by fluorescence. Visible bands were excised from
the gel, subjected to tryspin digestion and identified by LC/MS/
MS at NextGen Sciences (Ann Arbor, MI). Tandem mass spectra
were extracted by Xcalibur (ThermoFisher) rev. 2.0. All MS/MS
samples were analyzed using Mascot version 1.0 (Matrix Science,
London, UK; version Mascot) assuming digestion by the enzyme
trypsin. Protein identifications were accepted if they could be
established at greater than 90.0% probability by the Protein
Prophet algorithm [52] and contained at least two identified
peptides.
Supporting Information
Figure S1 Detection of cytokeratin 17 in BAL fluid after
i.n. SEA and BSS. Mice were immunized i.n. as described in
legend of figure 4 and BAL fluid harvested after 16 h. BAL fluid
were immunoblotted using anti-CK17 antibody. Data are from 1
experiment.
(TIF)
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Figure 5. Detection of cytokeratin 17 in BAL fluid after i.n. SEA. Mice were immunized i.n. as described in legend of figure 4. (A)
Immunostaining of the lungs was performed using a rabbit polyclonal antibody against cytokeratin 17 (CK17) and rabbit immunoglobulin control (Ig).
The data are representative of three independent experiments, magnification 100X. (B) Immunoblotting of 5x concentrated BAL fluid was performed
using a rabbit polyclonal against cytokeratin 17 (CK17) and rabbit IgG control. (C) BAL fluid harvested at different times after i.n. SEA immunization
and BAL fluid from naı¨ve mice were immunoblotted using anti- CK17 antibody. High exposure of the immunoblot revealed the presence of
cytokeratin 17 in most samples including the samples harvested from naı¨ve mice but with less intensity. The data show 3 separate experiments using
with 3 mice per time point for each experiment.
doi:10.1371/journal.pone.0040184.g005
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